Abstract: The present invention provides a method for treating a protein aggregation disease, including: administering a pharmaceutical composition comprising a compound represented by the following formula (I) to a subject in need thereof, wherein each R1, R2, R3, R4, R5 and R6 are defined in the specification.

Abstract: The present invention provides a use of a compound to prepare a pharmaceutical composition for treating abnormal ?-amyloid aggregation mediated diseases. The compound is represented by the following formula (I): wherein A, B, R1, R2, R3, R4, R5 and R6 are defined in the specification.

Abstract: The present invention relates to a method for treating spinocerebellar ataxias comprising administering a pharmaceutical composition comprising of therapeutically effective amounts of Paeonia lactiflora and Glycyrrhiza uralensis to a subject in need. The pharmaceutical composition reduces productions of reactive oxygen species and inflammatory factors to suppress polyglutamine aggregation.

Abstract: A method for treating tau-associated disease by administering a pharmaceutical composition comprising a tetrahydropyranol derivative to a subject in need is disclosed. Particularly, a method for treating Alzheimer's disease by administering a pharmaceutical composition comprising a tetrahydropyranol derivative to a subject in need is disclosed. The tetrahydropyranol derivatives have demonstrated their abilities for reducing tau aggregation.

Abstract: A method for treating tau-associated disease by administering a pharmaceutical composition comprising a tetrahydropyranol derivative to a subject in need is disclosed. Particularly, a method for treating Alzheimer's disease by administering a pharmaceutical composition comprising a tetrahydropyranol derivative to a subject in need is disclosed. The tetrahydropyranol derivatives have demonstrated their abilities for reducing tau aggregation.

Abstract: The present invention provides a use of a compound to prepare a pharmaceutical composition for treating abnormal ?-amyloid aggregation mediated diseases. The compound is represented by the following formula (I): wherein A, B, R1, R2, R3, R4, R5 and R6 are defined in the specification.

Abstract: A method for treating abnormal ?-amyloid mediated diseases is disclosed, comprising administering a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises an indolylquinoline derivative represented by the following formula 1:

Abstract: The invention relates to a novel use of the Chinese herb Glycyrrhiza inflata in treatment of neurodegenerative disorders. Particularly, the invention relates to the use of ammonium glycyrrhizinate and licochalcone A in targeting polyQ-mediated spinocerebellar ataxia.

Abstract: A method for treating a tau-associated disease is disclosed, which comprises the step of administering a pharmaceutical composition to a subject in need. Particularly, a method for treating Alzheimer's disease is disclosed, which comprises the step of administering a pharmaceutical composition to a subject in need.

Abstract: A method for treating tau-associated disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. Particularly, a method for treating Alzheimer's disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. The two disclosed quinoline derivatives have the inhibition effect for GSK-3? kinase activity, so as the two disclosed quinoline derivatives have the ability for inhibiting tau hyperphosphorylation or reducing tau aggregation.

Abstract: The present invention relates to a method for treating spinocerebellar ataxias comprising administering a pharmaceutical composition comprising of therapeutically effective amounts of Paeonia lactiflora and Glycyrrhiza uralensis to a subject in need. The pharmaceutical composition reduces productions of reactive oxygen species and inflammatory factors to suppress polyglutamine aggregation.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, wherein indole and an indole-based compound contained in a pharmaceutical composition used in the method of the present invention can reduce the polyglutamine aggregation through decreasing reactive oxygen species production and increasing the activity of chaperone and autophagy.

Abstract: A method for treating abnormal ?-amyloid mediated diseases is disclosed, comprising administering a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises an indolylquinoline derivative represented by the following formula 1:

Abstract: The invention relates to a novel use of the Chinese herb Glycyrrhiza inflata in treatment of neurodegenerative disorders. Particularly, the invention relates to the use of ammonium glycyrrhizinate and licochalcone A in targeting polyQ-mediated spinocerebellar ataxia.

Abstract: The present invention relates to a method for treating abnormal polyglutamine-mediated diseases comprising: administering a pharmaceutical composition comprising one or more selected from the group consisting of a Gardenia jasminoides extract, geniposide and crocin.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, wherein indole and an indole-based compound contained in a pharmaceutical composition used in the method of the present invention can reduce the polyglutamine aggregation through decreasing reactive oxygen species production and increasing the activity of chaperone and autophagy.

Abstract: A method for inhibiting spinocerebellar ataxia is disclosed, which comprises: administering an extract of Paeonia lactiflora to a subject in need; wherein a concentration of the extract of Paeonia lactiflora is in the range from 1 ?g/mL to 80 ?g/mL.

Abstract: A neuroblastoma host cell line for stably expressing human exogenous protein is provided. The cell line is generated by independently integrating control plasmid and switch plasmid into genome of human neuroblastoma SH-SY5Y cells. Upon inserting diseased gene into the above cell line, the cell line thus stably expresses the interested protein by induction, which can be used to study human neurological diseases related to the gene mutation.